metformin has been researched along with Lipodystrophy in 12 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Lipodystrophy: A collection of heterogenous conditions resulting from defective LIPID METABOLISM and characterized by ADIPOSE TISSUE atrophy. Often there is redistribution of body fat resulting in peripheral fat wasting and central adiposity. They include generalized, localized, congenital, and acquired lipodystrophy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the effects of the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone and metformin for treating HIV lipodystrophy." | 9.11 | Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. ( Cabezas, MC; de Koning, EJ; Hoepelman, AI; Joven, J; op't Roodt, J; Rabelink, TJ; van Wijk, JP, 2005) |
| "This study suggests that a relatively low dosage of metformin reduces insulin resistance and related cardiovascular risk parameters in HIV-infected patients with lipodystrophy." | 9.09 | Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. ( Basgoz, N; Corcoran, C; Davis, B; Grinspoon, S; Hadigan, C; Sax, P, 2000) |
| "To compare the effects of the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone and metformin for treating HIV lipodystrophy." | 5.11 | Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial. ( Cabezas, MC; de Koning, EJ; Hoepelman, AI; Joven, J; op't Roodt, J; Rabelink, TJ; van Wijk, JP, 2005) |
| "This study suggests that a relatively low dosage of metformin reduces insulin resistance and related cardiovascular risk parameters in HIV-infected patients with lipodystrophy." | 5.09 | Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. ( Basgoz, N; Corcoran, C; Davis, B; Grinspoon, S; Hadigan, C; Sax, P, 2000) |
| "Obesity is not necessary to observe insulin resistance in humans since severe insulin resistance also characterizes patients lacking subcutaneous fat such as those with HAART (highly-active antiretroviral therapy) - associated lipodystrophy." | 2.43 | The fatty liver and insulin resistance. ( Westerbacka, J; Yki-Järvinen, H, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (91.67) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guillín-Amarelle, C | 1 |
| Sánchez-Iglesias, S | 1 |
| Araújo-Vilar, D | 1 |
| Sattler, F | 1 |
| Sahhar, NN | 1 |
| Ahmad, AT | 1 |
| Ammari, FL | 1 |
| Ajlouni, KM | 1 |
| Yki-Järvinen, H | 1 |
| Westerbacka, J | 1 |
| van Wijk, JP | 2 |
| de Koning, EJ | 2 |
| Cabezas, MC | 1 |
| op't Roodt, J | 1 |
| Joven, J | 2 |
| Rabelink, TJ | 2 |
| Hoepelman, AI | 1 |
| Rooney, DP | 1 |
| Ryan, MF | 1 |
| Coll, B | 1 |
| Parra, S | 1 |
| Castro Cabezas, M | 1 |
| Hoepelman, IM | 1 |
| Alonso-Villaverde, C | 1 |
| Camps, J | 1 |
| Ferre, N | 1 |
| Tous, M | 1 |
| Currier, JS | 1 |
| Hadigan, C | 2 |
| Corcoran, C | 1 |
| Basgoz, N | 1 |
| Davis, B | 1 |
| Sax, P | 1 |
| Grinspoon, S | 1 |
| Meigs, JB | 1 |
| Rabe, J | 1 |
| D'Agostino, RB | 1 |
| Wilson, PW | 1 |
| Lipinska, I | 1 |
| Tofler, GH | 1 |
| Grinspoon, SS | 1 |
| Kotler, DP | 1 |
2 reviews available for metformin and Lipodystrophy
| Article | Year |
|---|---|
[Uncommon lipodystrophic syndromes].
Topics: Acro-Osteolysis; Adipose Tissue; Aging, Premature; Body Composition; Cardiovascular System; Combined | 2015 |
The fatty liver and insulin resistance.
Topics: Adiponectin; Adipose Tissue; Alanine Transaminase; Animals; Antiretroviral Therapy, Highly Active; C | 2005 |
4 trials available for metformin and Lipodystrophy
| Article | Year |
|---|---|
Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial.
Topics: Adipose Tissue; Adolescent; Adult; Aged; Blood Glucose; Brachial Artery; Endothelium, Vascular; Fatt | 2005 |
Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy.
Topics: Adult; Anti-Inflammatory Agents; Antioxidants; Aryldialkylphosphatase; Chemokine CCL2; Cholesterol, | 2006 |
Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial.
Topics: Adult; Area Under Curve; Blood Glucose; Double-Blind Method; Female; HIV Infections; Humans; Hyperin | 2000 |
Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance.
Topics: Adipose Tissue; Adult; Cross-Sectional Studies; Female; HIV Infections; Humans; Hypoglycemic Agents; | 2001 |
6 other studies available for metformin and Lipodystrophy
| Article | Year |
|---|---|
Body habitus changes related to lipodystrophy.
Topics: Androgens; Exercise; Growth Hormone; HIV Infections; Humans; Incidence; Lipodystrophy; Metformin; Pr | 2003 |
Dysregulation of growth hormone in acquired generalized lipodystrophy.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administrati | 2004 |
Summaries for patients. HIV lipodystrophy: rosiglitazone or metformin?
Topics: Adipose Tissue; Adolescent; Adult; Aged; Blood Glucose; Brachial Artery; Endothelium, Vascular; Fatt | 2005 |
Diabetes with partial lipodystrophy following sclerodermatous chronic graft vs. host disease.
Topics: Adolescent; Bone Marrow Transplantation; Diabetes Mellitus, Type 2; Female; Graft vs Host Disease; H | 2006 |
How to manage metabolic complications of HIV therapy: what to do while we wait for answers.
Topics: Anabolic Agents; Anti-HIV Agents; Anticholesteremic Agents; Atorvastatin; Exercise Therapy; Gemfibro | 2000 |
Metabolic alterations in HIV lipodystrophy. IAPAC sessions 2001, July 18-19, 2001 - Chicago.
Topics: Acidosis; Anti-HIV Agents; Bone Diseases, Metabolic; Cost-Benefit Analysis; Glucose; Glucose Intoler | 2001 |